Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper
Hill, Loreena; Prager Geller, Tal; Baruah, Resham; Beattie, James M.; Boyne, Josiane; de Stoutz, Noemi; Di Stolfo, Giuseppe; Lambrinou, Ekaterini; Skibelund, Anne K.; Uchmanowicz, Izabella; Rutten, Frans H.; Čelutkienė, Jelena; Piepoli, Massimo Francesco; Jankowska, Ewa A.; Chioncel, Ovidiu; Ben Gal, Tuvia; Seferovic, Petar M.; Ruschitzka, Frank; Coats, Andrew J.S.; Strömberg, Anna; Jaarsma, Tiny
(2020) European Journal of Heart Failure, volume 22, issue 12, pp. 2327 - 2339
(Article)
Abstract
The Heart Failure Association of the European Society of Cardiology has published a previous position paper and various guidelines over the past decade recognizing the value of palliative care for those affected by this burdensome condition. Integrating palliative care into evidence-based heart failure management remains challenging for many professionals, as
... read more
it includes the identification of palliative care needs, symptom control, adjustment of drug and device therapy, advance care planning, family and informal caregiver support, and trying to ensure a ‘good death’. This new position paper aims to provide day-to-day practical clinical guidance on these topics, supporting the coordinated provision of palliation strategies as goals of care fluctuate along the heart failure disease trajectory. The specific components of palliative care for symptom alleviation, spiritual and psychosocial support, and the appropriate modification of guideline-directed treatment protocols, including drug deprescription and device deactivation, are described for the chronic, crisis and terminal phases of heart failure.
show less
Download/Full Text
Keywords: Clinical guidance, Heart failure, Palliative care, Cardiology and Cardiovascular Medicine, Journal Article
ISSN: 1388-9842
Publisher: Oxford University Press
Note: Funding Information: This paper has been supported by the Patient Forum of the European Society of Cardiology. Funding Information: This paper has been supported by the Patient Forum of the European Society of Cardiology. Conflict of interest: L.H. personal fees from Novartis; R.B. personal fees from Novartis, Boehringer; J.M.B. personal fees from Vifor; G.D.S. grants from Italian Health Ministry, Daiichi Sankyo, Boston Scientific, Lusofarmaco and personal fees from Novartis; F.H.R. grants from Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Bayer; J.?. personal fees from Servier, Novartis, AstraZeneca, Boehringer Ingelheim, Amgen; O.C. grants from Servier, Novartis, Vifor, Boehringer Ingelheim; F.R. no personal payments, all payments directly to the University of Zurich since 2018; A.J.S.C. personal fees from AstraZeneca, Bayer, Menarini, Novartis, Nutricia, Servier, Vifor, Acrtimed, Cardiac Dimensions, Enopace, Impulse Dynamics, CVRx, Faraday, Gore, Respicardia, Corvia, Arena, ESN Cleer. The other authors have nothing to disclose. Publisher Copyright: © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
(Peer reviewed)